Does the media prefer ALGS or HURA?

In the previous week, TuHURA Biosciences had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for TuHURA Biosciences and 2 mentions for Aligos Therapeutics. TuHURA Biosciences' average media sentiment score of 1.16 beat Aligos Therapeutics' score of 0.94 indicating that TuHURA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALGS or ENGN more profitable?

enGene has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. enGene's return on equity of -27.97% beat Aligos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aligos Therapeutics -241.01% -160.72% -92.30% enGene N/A -27.97% -22.65%

Does the media prefer ALGS or ENGN?

In the previous week, enGene had 27 more articles in the media than Aligos Therapeutics. MarketBeat recorded 29 mentions for enGene and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.94 beat enGene's score of 0.36 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 4 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Aligos Therapeutics (ALGS) Competitors

$5.12 -0.10 (-1.84%)

As of 11:17 AM Eastern

Compare

ALGS vs. BMEA, IMDX, OKUR, HURA, and ENGN

Should you buy Aligos Therapeutics stock or one of its competitors? Aligos Therapeutics's main competitors and comparable companies include Biomea Fusion (BMEA), Oncocyte (IMDX), OnKure Therapeutics (OKUR), TuHURA Biosciences (HURA), and enGene (ENGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aligos Therapeutics compare to Biomea Fusion?

Aligos Therapeutics (NASDAQ:ALGS) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Aligos Therapeutics has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.23, suggesting that its share price is 123% less volatile than the broader market.

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aligos Therapeutics currently has a consensus price target of $38.50, indicating a potential upside of 651.37%. Biomea Fusion has a consensus price target of $9.00, indicating a potential upside of 422.95%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aligos Therapeutics is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Biomea Fusion has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Aligos Therapeutics' return on equity of -160.72% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Biomea Fusion	N/A	-253.73%	-97.91%

In the previous week, Aligos Therapeutics had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 2 mentions for Aligos Therapeutics and 1 mentions for Biomea Fusion. Aligos Therapeutics' average media sentiment score of 0.94 beat Biomea Fusion's score of 0.85 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
Biomea Fusion	Positive

Aligos Therapeutics has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.60	-$24.19M	-$7.30	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A

Summary

Aligos Therapeutics beats Biomea Fusion on 11 of the 15 factors compared between the two stocks.

How does Aligos Therapeutics compare to Oncocyte?

Aligos Therapeutics (NASDAQ:ALGS) and Oncocyte (NASDAQ:IMDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Aligos Therapeutics has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

Aligos Therapeutics currently has a consensus price target of $38.50, suggesting a potential upside of 651.37%. Oncocyte has a consensus price target of $10.50, suggesting a potential upside of 155.85%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aligos Therapeutics is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Aligos Therapeutics has higher earnings, but lower revenue than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.60	-$24.19M	-$7.30	N/A
Oncocyte	$4.05M	33.16	-$50.22M	-$1.49	N/A

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 55.4% of Oncocyte shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 2.2% of Oncocyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Aligos Therapeutics had 1 more articles in the media than Oncocyte. MarketBeat recorded 2 mentions for Aligos Therapeutics and 1 mentions for Oncocyte. Oncocyte's average media sentiment score of 1.89 beat Aligos Therapeutics' score of 0.94 indicating that Oncocyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
Oncocyte	Very Positive

Aligos Therapeutics has a net margin of -241.01% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Oncocyte	-2,955.63%	N/A	-107.52%

Summary

Aligos Therapeutics beats Oncocyte on 12 of the 17 factors compared between the two stocks.

How does Aligos Therapeutics compare to OnKure Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

OnKure Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. OnKure Therapeutics' return on equity of -49.01% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
OnKure Therapeutics	N/A	-49.01%	-45.77%

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 2.2% of OnKure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aligos Therapeutics has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

Aligos Therapeutics currently has a consensus target price of $38.50, suggesting a potential upside of 651.37%. OnKure Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 481.78%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aligos Therapeutics is more favorable than OnKure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Aligos Therapeutics has higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.60	-$24.19M	-$7.30	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

In the previous week, Aligos Therapeutics had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 2 mentions for Aligos Therapeutics and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.87 beat Aligos Therapeutics' score of 0.94 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
OnKure Therapeutics	Very Positive

Summary

Aligos Therapeutics beats OnKure Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to TuHURA Biosciences?

Aligos Therapeutics (NASDAQ:ALGS) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

TuHURA Biosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. TuHURA Biosciences' return on equity of -156.47% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
TuHURA Biosciences	N/A	-156.47%	-106.98%

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 651.37%. TuHURA Biosciences has a consensus target price of $9.00, indicating a potential upside of 325.53%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aligos Therapeutics is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aligos Therapeutics has higher revenue and earnings than TuHURA Biosciences. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.60	-$24.19M	-$7.30	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A

Aligos Therapeutics has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market.

In the previous week, TuHURA Biosciences had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for TuHURA Biosciences and 2 mentions for Aligos Therapeutics. TuHURA Biosciences' average media sentiment score of 1.16 beat Aligos Therapeutics' score of 0.94 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aligos Therapeutics beats TuHURA Biosciences on 10 of the 15 factors compared between the two stocks.

How does Aligos Therapeutics compare to enGene?

Aligos Therapeutics (NASDAQ:ALGS) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Aligos Therapeutics presently has a consensus price target of $38.50, indicating a potential upside of 651.37%. enGene has a consensus price target of $11.05, indicating a potential upside of 505.23%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aligos Therapeutics is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Aligos Therapeutics has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market. Comparatively, enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market.

Aligos Therapeutics has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.60	-$24.19M	-$7.30	N/A
enGene	N/A	N/A	-$117.30M	-$1.13	N/A

In the previous week, enGene had 27 more articles in the media than Aligos Therapeutics. MarketBeat recorded 29 mentions for enGene and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.94 beat enGene's score of 0.36 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
enGene	4 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

enGene has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. enGene's return on equity of -27.97% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
enGene	N/A	-27.97%	-22.65%

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 10.5% of enGene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Aligos Therapeutics beats enGene on 9 of the 16 factors compared between the two stocks.

Get Aligos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALGS vs. The Competition

Export

Metric	Aligos Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$31.97M	$3.87B	$7.20B	$12.67B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-0.70	15.12	275.02	25.43
Price / Sales	14.60	1,415.04	638.08	88.25
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	0.59	15.06	10.32	6.23
Net Income	-$24.19M	-$22.86M	$3.50B	$358.31M
7 Day Performance	-17.49%	-2.17%	-2.41%	-1.59%
1 Month Performance	-25.63%	1.84%	0.22%	-2.89%
1 Year Performance	-49.76%	42.42%	24.17%	8.22%

Aligos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALGS Aligos Therapeutics	2.6448 of 5 stars	$5.12 -1.8%	$38.50 +651.4%	-48.8%	$31.97M	$2.19M	N/A	90	News Coverage
BMEA Biomea Fusion	1.8867 of 5 stars	$1.93 -4.9%	$9.00 +366.3%	-9.8%	$139.89M	N/A	N/A	50
IMDX Oncocyte	2.8688 of 5 stars	$4.27 +3.4%	$10.50 +145.9%	N/A	$139.71M	$4.05M	N/A	120
OKUR OnKure Therapeutics	3.21 of 5 stars	$3.40 -5.0%	$17.50 +414.7%	+26.5%	$137.36M	N/A	N/A	N/A
HURA TuHURA Biosciences	2.04 of 5 stars	$2.12 -0.9%	$9.00 +324.5%	-18.0%	$135.10M	N/A	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALGS) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aligos Therapeutics (ALGS) Competitors

ALGS vs. BMEA, IMDX, OKUR, HURA, and ENGN

How does Aligos Therapeutics compare to Biomea Fusion?

Summary

How does Aligos Therapeutics compare to Oncocyte?

Summary

How does Aligos Therapeutics compare to OnKure Therapeutics?

Summary

How does Aligos Therapeutics compare to TuHURA Biosciences?

Summary

How does Aligos Therapeutics compare to enGene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aligos Therapeutics (ALGS) Competitors

ALGS vs. BMEA, IMDX, OKUR, HURA, and ENGN

How does Aligos Therapeutics compare to Biomea Fusion?

Which has more volatility & risk, ALGS or BMEA?

Do insiders and institutionals believe in ALGS or BMEA?

Do analysts recommend ALGS or BMEA?

Is ALGS or BMEA more profitable?

Does the media favor ALGS or BMEA?

Which has higher earnings and valuation, ALGS or BMEA?

Summary

How does Aligos Therapeutics compare to Oncocyte?

Which has more risk and volatility, ALGS or IMDX?

Do analysts rate ALGS or IMDX?

Which has preferable valuation and earnings, ALGS or IMDX?

Do institutionals and insiders have more ownership in ALGS or IMDX?

Does the media prefer ALGS or IMDX?

Is ALGS or IMDX more profitable?

Summary

How does Aligos Therapeutics compare to OnKure Therapeutics?

Is ALGS or OKUR more profitable?

Do institutionals & insiders have more ownership in ALGS or OKUR?

Which has more volatility & risk, ALGS or OKUR?

Do analysts recommend ALGS or OKUR?

Which has preferable earnings and valuation, ALGS or OKUR?

Does the media prefer ALGS or OKUR?

Summary

How does Aligos Therapeutics compare to TuHURA Biosciences?

Is ALGS or HURA more profitable?

Do analysts prefer ALGS or HURA?

Do institutionals and insiders believe in ALGS or HURA?

Which has better earnings and valuation, ALGS or HURA?

Which has more volatility and risk, ALGS or HURA?

Does the media prefer ALGS or HURA?

Summary

How does Aligos Therapeutics compare to enGene?

Do analysts rate ALGS or ENGN?

Which has more volatility and risk, ALGS or ENGN?

Which has higher valuation and earnings, ALGS or ENGN?

Does the media prefer ALGS or ENGN?

Is ALGS or ENGN more profitable?

Do insiders & institutionals have more ownership in ALGS or ENGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools